Considering its potential to intricately alter genetic DNA, the CRISPR technology is being widely used to develop viable therapeutics for the treatment of rare and complex genetic disorders, which are currently considered untreatable
Roots Analysis has announced the addition of “CRISPR based Therapeutics Market, 2021-2030” report to its list of offerings.
With over 115 candidates under development for various indications, the future of this niche market seems promising. The year 2020 was particularly eventful, with Emmanuelle Charpentier and Jennifer Doudna receiving the Nobel Prize for their work on the CRISPR technology and several other important milestones, such as the approval of CRISPR based diagnostics for COVID-19, discovery of novel Cas proteins, and the progression of promising leads based on this technology, in clinical trials. Promising trial results have garnered the attention of notable investors in the healthcare sector and the current focus of research in this field is on developing advanced delivery vehicles for CRISPR based therapeutics.
To order this 250+ page report, which features 75+ figures and 70+ tables, please visit https://www.rootsanalysis.com/reports/crispr-based-therapeutics-market.html